90% efficacy for Pfizer's COVID-19 mRNA vaccine is striking. But we need to wait for the full data
- Written by Harry Al-Wassiti, Bioengineer and Research Fellow, Monash University
German biotech company BioNTech and US pharmaceutical Pfizer announced on Monday promising early results from their phase 3 clinical trial for a vaccine against SARS-CoV-2, the virus that causes COVID-19.
These early results are what is known as an “interim analysis”. It’s an early look at the data before a study is complete, to...





